DFTX
Definium Therapeutics, Inc.Company with tickers: DFTX
CIK
1813814
CUSIP
24477V105
Shares Outstanding
109,066,783
13F Activity (30d)
217 filings
217 filers
| Line Item | Value | Unit | Period End | Form | Filed |
|---|---|---|---|---|---|
| Revenue | — | ||||
| Revenue (ASC 606) | — | ||||
| Cost of Revenue | — | ||||
| Gross Profit | — | ||||
| Operating Expenses | $59,220,000 | USD | 2026-03-31 | 10-Q | 2026-05-07 |
| Research & Development | $41,484,000 | USD | 2026-03-31 | 10-Q | 2026-05-07 |
| Operating Income | $-59,220,000 | USD | 2026-03-31 | 10-Q | 2026-05-07 |
| Net Income | $-77,098,000 | USD | 2026-03-31 | 10-Q | 2026-05-07 |
| EPS (Basic) | $-0.71 | USD/shares | 2026-03-31 | 10-Q | 2026-05-07 |
| EPS (Diluted) | $-0.71 | USD/shares | 2026-03-31 | 10-Q | 2026-05-07 |